Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer

Merck & Co Inc MRK and Eisai Co Ltd ESALY presented final analysis results from Phase 3 LEAP-002 of Keytruda plus Lenvima versus Lenvima as a first-line treatment for unresectable hepatocellular carcinoma (uHCC).
In the final analysis of the trial, there was a trend toward improvement for one of the study's dual primary endpoints, overall survival (OS); however, the results did not meet statistical significance.
Related: Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal.
The median OS was 21.2 months for Keytruda plus Lenvima and 19.0 months for Lenvima monotherapy.
Additionally, Keytruda plus Lenvima resulted in a trend toward improvement in progression-free survival (PFS) versus Lenvima monotherapy; however, the results did not meet the pre-specified threshold at the first interim analysis for statistical significance.
Price Action: MRK shares closed lower by 0.09% at $87.34 on Friday.